Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847387 | 0.82 | GRM1 (0.50) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL7838136 | 0.80 | GRM5 (0.55) | GRM1GRM5PDK4JAK1NAMPT | |
| SCHEMBL31169216 | 0.80 | GRM1 (0.49) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL4462806 | 0.77 | GRM1 (0.51) | GRM1GRM5PDK4JAK1NAMPT | |
| SCHEMBL12523749 | 0.77 | NAMPT (0.53) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL17645656 | 0.76 | CDK9 (0.49) | GRM1GRM5PDK4JAK1NAMPT | |
| SCHEMBL25480230 | 0.76 | GRM1 (0.59) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL31466070 | 0.76 | GRM1 (0.53) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL14849746 | 0.76 | GRM1 (0.48) | GRM1GRM5PDK4JAK1GPR119 | |
| SCHEMBL8912847 | 0.76 | NAMPT (0.63) | GRM1GRM5PDK4GPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | GRM1 810/4885GRM5 1943/4885PDK4 1735/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | GRM1 1017/4885GRM5 2202/4885PDK4 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.